Convatec and Lilly Foundation Commit $5 Million to Partners In Health
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Newsfilter
- Financial Commitment: Convatec and the Lilly Foundation have pledged approximately $5 million to support Partners In Health (PIH), aiming to accelerate the integration of non-communicable diseases (NCDs) and chronic care into primary and community health systems in resource-limited settings, which is expected to benefit more patients.
- Collaboration Expansion: This financial commitment marks the next phase of Convatec's collaboration with PIH, which has already reached over 300,000 people since 2023, further promoting the training and deployment of Community Health Workers to enhance the quality of local care for chronic disease patients.
- Educational Partnership: The new phase will introduce collaboration with the University of Global Health Equity in Rwanda, aiming to prepare the next generation of changemakers to build equitable health systems through innovation and clinical evidence, which has significant social implications.
- Long-term Commitment: Convatec will continue to support PIH through financial contributions, product donations, and technical expertise, ensuring systematic strengthening in multiple countries, including Peru and Rwanda, to improve early diagnosis and continuity of care, driving sustainable health improvements.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1131.420
Low
950.00
Averages
1192
High
1500
Current: 1131.420
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zealand Pharma's Phase III Trial Results Disappointing
- Disappointing Trial Results: Zealand Pharma's Phase III trial of Survodutide revealed a 19% dropout rate due to adverse effects, causing the company's shares to plummet nearly 23%, indicating a significant impact on its competitiveness in the weight-loss drug market.
- Diminished Competitive Edge: The disappointing results further solidify Eli Lilly and Novo Nordisk's dominance in the GLP-1 market, reducing competitive pressure and helping them maintain market share and pricing power.
- Positive Data for Eli Lilly: At the American Diabetes Association meeting, Eli Lilly presented promising data for Retatrutide, with participants achieving an average weight loss of about 19% and only a 4% dropout rate, indicating an expanding competitive advantage in the weight-loss drug sector.
- Divergent Market Reactions: While Eli Lilly's stock rose approximately 2.5% due to the new data, Novo Nordisk's shares declined amid increasing competition, reflecting a clear divergence in market performance between the two companies.
See More
Eli Lilly's Retatrutide Trial Shows Significant Weight Loss
- Clinical Trial Results: Eli Lilly presented pivotal TRIUMPH-1 study results at the American Diabetes Association meeting, revealing that adults with obesity receiving 12 mg of Retatrutide lost an average of 70.3 pounds (28.3% of body weight) over 80 weeks, with 65.3% achieving a BMI below 30 and 33.3% reaching a healthy BMI under 25, indicating significant weight loss efficacy.
- Sustained Weight Loss: In a pre-specified extension for participants with a BMI ≥ 35, the average weight loss sustained over 104 weeks reached 85 pounds (30.3%), demonstrating Retatrutide's long-term effectiveness and potential market competitiveness.
- Multiple Health Benefits: Beyond weight loss, Retatrutide achieved up to 73.1% pain score reduction in knee osteoarthritis patients and a 60.6% reduction in severity for those with moderate-to-severe obstructive sleep apnea, highlighting its potential in addressing obesity-related health issues.
- Cardiometabolic Improvements: In the TRANSCEND-T2D-1 trial, type 2 diabetes participants experienced HbA1c reductions of up to 2.0% and weight loss of 36.6 pounds (16.8%), with triglycerides reduced by up to 41% and systolic blood pressure lowered by 12.3 mmHg, showcasing broad cardiometabolic health benefits of the drug.
See More
Eli Lilly Releases Results from Three Phase 3 Trials of Orforglipron
- Significant Trial Results: In the ACHIEVE-2 trial, Orforglipron achieved an average HbA1C reduction of 1.7% over 40 weeks, significantly outperforming dapagliflozin's 0.8%, indicating its potential in improving blood sugar control for diabetes patients.
- International Participation: The ACHIEVE-3 trial involved 1,698 participants, with Orforglipron lowering HbA1C by 1.9% and 2.2% at 9 mg and 17.2 mg doses respectively, demonstrating its efficacy across diverse populations and potentially enhancing its market competitiveness.
- Safety Concerns: Despite showing good efficacy, the treatment discontinuation rates due to adverse events in ACHIEVE-3 were 8.7% and 9.7%, higher than oral semaglutide's 4.5%, which may affect its market acceptance and prescribing patterns.
- Future Plans: Based on the trial results, Lilly plans to submit Orforglipron for FDA approval by the end of Q2 2026, which, if approved, will further solidify its position in the diabetes treatment market.
See More
Convatec and Lilly Foundation Commit $5 Million to Partners In Health
- Financial Commitment: Convatec and the Lilly Foundation have pledged approximately $5 million to support Partners In Health (PIH), aiming to accelerate the integration of non-communicable diseases (NCDs) and chronic care into primary and community health systems in resource-limited settings, which is expected to benefit more patients.
- Collaboration Expansion: This financial commitment marks the next phase of Convatec's collaboration with PIH, which has already reached over 300,000 people since 2023, further promoting the training and deployment of Community Health Workers to enhance the quality of local care for chronic disease patients.
- Educational Partnership: The new phase will introduce collaboration with the University of Global Health Equity in Rwanda, aiming to prepare the next generation of changemakers to build equitable health systems through innovation and clinical evidence, which has significant social implications.
- Long-term Commitment: Convatec will continue to support PIH through financial contributions, product donations, and technical expertise, ensuring systematic strengthening in multiple countries, including Peru and Rwanda, to improve early diagnosis and continuity of care, driving sustainable health improvements.
See More
Roche Maintains Investment Plans in Germany Amid Competitors' Cuts
- Commitment to Investment: Roche has confirmed its €600 million ($692.88 million) investment in a new diagnostic production site in Penzberg, Germany, despite competitors like Eli Lilly and Boehringer Ingelheim scaling back due to government healthcare cost-cutting measures.
- Construction Timeline: This project represents Roche's largest single investment in Germany, with construction expected to be completed by 2027, demonstrating the company's long-term commitment to the German market despite policy uncertainties.
- Policy Impact Assessment: CEO Daniel Steiners highlighted that the government's decisions are creating new uncertainties regarding investment, research, and production decisions, potentially causing significant economic damage with minimal benefits for a sustainable healthcare system.
- Future Investment Review: Roche indicated it would carefully review future investments in Germany, reflecting sensitivity to policy changes and adaptability to the market environment.
See More
Space Pharma Market Thrives Amidst Mega-IPO Frenzy
- Market Potential: Morgan Stanley predicts that the space economy could exceed $1 trillion by 2040, with the pharmaceutical sector likely to experience the most immediate disruption, prompting a growing number of companies to explore drug development in low Earth orbit.
- Technological Breakthroughs: Redwire's SpaceMD has successfully flown 54 PIL-BOX units and tested 37 drug compounds, leveraging the zero-gravity environment to produce more uniform drug crystals, thereby enhancing drug absorbability and stability.
- Strengthened Partnerships: SpaceMD's collaboration with pharmaceutical giants like Eli Lilly and Bristol Myers Squibb showcases the potential of new crystal forms, driving the development of new drug candidates and highlighting the commercial viability of space pharmaceuticals.
- Future Directions: As the International Space Station approaches retirement, SpaceMD is establishing relationships with commercial low Earth orbit destination providers, aiming for increased flight frequency and the development of fixed infrastructure to support the long-term growth of space pharmaceuticals.
See More
Zealand Pharma's Phase III Trial Results Disappointing
- Disappointing Trial Results: Zealand Pharma's Phase III trial of Survodutide revealed a 19% dropout rate due to adverse effects, causing the company's shares to plummet nearly 23%, indicating a significant impact on its competitiveness in the weight-loss drug market.
- Diminished Competitive Edge: The disappointing results further solidify Eli Lilly and Novo Nordisk's dominance in the GLP-1 market, reducing competitive pressure and helping them maintain market share and pricing power.
- Positive Data for Eli Lilly: At the American Diabetes Association meeting, Eli Lilly presented promising data for Retatrutide, with participants achieving an average weight loss of about 19% and only a 4% dropout rate, indicating an expanding competitive advantage in the weight-loss drug sector.
- Divergent Market Reactions: While Eli Lilly's stock rose approximately 2.5% due to the new data, Novo Nordisk's shares declined amid increasing competition, reflecting a clear divergence in market performance between the two companies.
See More
Eli Lilly's Retatrutide Trial Shows Significant Weight Loss
- Clinical Trial Results: Eli Lilly presented pivotal TRIUMPH-1 study results at the American Diabetes Association meeting, revealing that adults with obesity receiving 12 mg of Retatrutide lost an average of 70.3 pounds (28.3% of body weight) over 80 weeks, with 65.3% achieving a BMI below 30 and 33.3% reaching a healthy BMI under 25, indicating significant weight loss efficacy.
- Sustained Weight Loss: In a pre-specified extension for participants with a BMI ≥ 35, the average weight loss sustained over 104 weeks reached 85 pounds (30.3%), demonstrating Retatrutide's long-term effectiveness and potential market competitiveness.
- Multiple Health Benefits: Beyond weight loss, Retatrutide achieved up to 73.1% pain score reduction in knee osteoarthritis patients and a 60.6% reduction in severity for those with moderate-to-severe obstructive sleep apnea, highlighting its potential in addressing obesity-related health issues.
- Cardiometabolic Improvements: In the TRANSCEND-T2D-1 trial, type 2 diabetes participants experienced HbA1c reductions of up to 2.0% and weight loss of 36.6 pounds (16.8%), with triglycerides reduced by up to 41% and systolic blood pressure lowered by 12.3 mmHg, showcasing broad cardiometabolic health benefits of the drug.
See More
Eli Lilly Releases Results from Three Phase 3 Trials of Orforglipron
- Significant Trial Results: In the ACHIEVE-2 trial, Orforglipron achieved an average HbA1C reduction of 1.7% over 40 weeks, significantly outperforming dapagliflozin's 0.8%, indicating its potential in improving blood sugar control for diabetes patients.
- International Participation: The ACHIEVE-3 trial involved 1,698 participants, with Orforglipron lowering HbA1C by 1.9% and 2.2% at 9 mg and 17.2 mg doses respectively, demonstrating its efficacy across diverse populations and potentially enhancing its market competitiveness.
- Safety Concerns: Despite showing good efficacy, the treatment discontinuation rates due to adverse events in ACHIEVE-3 were 8.7% and 9.7%, higher than oral semaglutide's 4.5%, which may affect its market acceptance and prescribing patterns.
- Future Plans: Based on the trial results, Lilly plans to submit Orforglipron for FDA approval by the end of Q2 2026, which, if approved, will further solidify its position in the diabetes treatment market.
See More
Convatec and Lilly Foundation Commit $5 Million to Partners In Health
- Financial Commitment: Convatec and the Lilly Foundation have pledged approximately $5 million to support Partners In Health (PIH), aiming to accelerate the integration of non-communicable diseases (NCDs) and chronic care into primary and community health systems in resource-limited settings, which is expected to benefit more patients.
- Collaboration Expansion: This financial commitment marks the next phase of Convatec's collaboration with PIH, which has already reached over 300,000 people since 2023, further promoting the training and deployment of Community Health Workers to enhance the quality of local care for chronic disease patients.
- Educational Partnership: The new phase will introduce collaboration with the University of Global Health Equity in Rwanda, aiming to prepare the next generation of changemakers to build equitable health systems through innovation and clinical evidence, which has significant social implications.
- Long-term Commitment: Convatec will continue to support PIH through financial contributions, product donations, and technical expertise, ensuring systematic strengthening in multiple countries, including Peru and Rwanda, to improve early diagnosis and continuity of care, driving sustainable health improvements.
See More
Roche Maintains Investment Plans in Germany Amid Competitors' Cuts
- Commitment to Investment: Roche has confirmed its €600 million ($692.88 million) investment in a new diagnostic production site in Penzberg, Germany, despite competitors like Eli Lilly and Boehringer Ingelheim scaling back due to government healthcare cost-cutting measures.
- Construction Timeline: This project represents Roche's largest single investment in Germany, with construction expected to be completed by 2027, demonstrating the company's long-term commitment to the German market despite policy uncertainties.
- Policy Impact Assessment: CEO Daniel Steiners highlighted that the government's decisions are creating new uncertainties regarding investment, research, and production decisions, potentially causing significant economic damage with minimal benefits for a sustainable healthcare system.
- Future Investment Review: Roche indicated it would carefully review future investments in Germany, reflecting sensitivity to policy changes and adaptability to the market environment.
See More
Space Pharma Market Thrives Amidst Mega-IPO Frenzy
- Market Potential: Morgan Stanley predicts that the space economy could exceed $1 trillion by 2040, with the pharmaceutical sector likely to experience the most immediate disruption, prompting a growing number of companies to explore drug development in low Earth orbit.
- Technological Breakthroughs: Redwire's SpaceMD has successfully flown 54 PIL-BOX units and tested 37 drug compounds, leveraging the zero-gravity environment to produce more uniform drug crystals, thereby enhancing drug absorbability and stability.
- Strengthened Partnerships: SpaceMD's collaboration with pharmaceutical giants like Eli Lilly and Bristol Myers Squibb showcases the potential of new crystal forms, driving the development of new drug candidates and highlighting the commercial viability of space pharmaceuticals.
- Future Directions: As the International Space Station approaches retirement, SpaceMD is establishing relationships with commercial low Earth orbit destination providers, aiming for increased flight frequency and the development of fixed infrastructure to support the long-term growth of space pharmaceuticals.
See More
